Indaptus Therapeutics Inc is a clinical biotechnology company that has developed a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy... Show more
Indaptus Therapeutics, Inc. is a clinical-stage biotechnology company developing immunotherapies intended to treat cancer and certain viral infections. Investors follow INDP because the company represents a speculative, early-stage bet on a novel approach to activating the body's immune system. Unlike established pharmaceutical firms, Indaptus generates no meaningful product revenue and is still working to advance its lead candidate through clinical development.
Indaptus Therapeutics is headquartered at 3 Columbus Circle in New York, New York. The company was previously named Intec Parent, Inc. and adopted the Indaptus Therapeutics name in August 2021. Its shares trade on the Nasdaq Capital Market under the symbol INDP. The company operates within the healthcare sector and the biotechnology industry, an area defined by long development timelines, heavy research spending, and substantial regulatory oversight from agencies such as the U.S. Food and Drug Administration (FDA).
Indaptus is built around what it calls the "Decoy" platform, a technology based on single strains of attenuated (weakened) and killed, non-pathogenic Gram-negative bacteria. The core scientific premise is that triggering a broad package of immune-system signals—rather than a single pathway—can produce stronger anti-tumor and anti-viral responses. These bacterial "decoys" are designed to activate multiple immune receptors, including Toll-like receptors (TLRs), NOD-like receptors (NLRs), and the STING (Stimulator of Interferon Genes) pathway, which work together to alert and mobilize the immune system.
The company's lead clinical candidate is Decoy20. Indaptus has studied Decoy20 for the treatment of advanced solid tumors and has reported preclinical activity against chronic hepatitis B virus (HBV) and human immunodeficiency virus (HIV) infections. As a clinical-stage company, its primary revenue sources are essentially nonexistent; instead, the business model depends on raising capital through equity financings to fund ongoing research, clinical trials, and general operations.
Indaptus occupies a niche position within the crowded immuno-oncology field. Its differentiated angle is the use of inactivated bacteria to deliver a multi-targeted immune stimulus intravenously, an approach the company positions as distinct from single-agent checkpoint inhibitors and other more narrowly targeted immunotherapies. However, the company competes against far larger biotechnology and pharmaceutical firms with deeper resources, broader pipelines, and established commercial infrastructure. Because its candidates remain in clinical and preclinical stages, Indaptus has not yet established a commercial market position or proven the efficacy and safety of its platform in large-scale trials.
Investor interest in INDP centers on its potential as an early-stage platform play. A successful Decoy20 trial or partnership could validate the underlying technology and dramatically reshape the company's financial profile, which currently shows no product revenue and ongoing net losses typical of pre-commercial biotechs. The company's broad applicability—spanning oncology and chronic viral infections—offers a potentially large addressable market if the platform proves effective.
Recent corporate developments have also drawn attention. In June 2025, Indaptus completed a 1-for-28 reverse stock split to support its Nasdaq listing. In December 2025, the company entered into a securities purchase agreement with investor David E. Lazar, who acquired preferred stock and became the beneficial owner of roughly 96% of the company's common stock on an as-converted, fully diluted basis. As part of that transaction, Indaptus announced plans to pursue a strategic transaction involving an investment in or acquisition of an operating business—an initiative that has shifted the company's direction beyond its original drug-development focus.
Indaptus carries the elevated risks typical of clinical-stage biotechnology companies. The company has a limited operating history, is not profitable, and has disclosed in its SEC filings that conditions exist that raise substantial doubt about its ability to continue as a going concern. It will likely need to raise additional capital, which can dilute existing shareholders.
Beyond funding risk, the company faces the inherent uncertainty of clinical trials, which are lengthy, expensive, and may fail to demonstrate safety or efficacy. Regulatory approval is not guaranteed, and even successful science may not translate into commercial success. The recent change in control and the planned pursuit of a strategic business combination add further uncertainty, including potential management changes, significant shareholder dilution, and reduced voting power for existing stockholders. Investors should also note that micro-cap biotech stocks can be highly volatile and illiquid.
Tickeron's AI Screener is an AI-powered stock and ETF discovery platform that helps traders and investors identify opportunities using technical indicators, fundamentals, volatility, trends, AI-generated signals, industries, price patterns, and customizable filters. Users can efficiently screen thousands of stocks and ETFs to surface ideas that align with their own investment strategies. Whether you are researching early-stage biotech names like INDP or building a diversified watchlist, the AI Screener offers a structured way to narrow the field.
Indaptus Therapeutics is a small, clinical-stage biotechnology company pursuing an unconventional immunotherapy platform aimed at both cancer and chronic viral infections. Its pre-revenue business model, reliance on external capital, and ongoing strategic repositioning make it a high-risk, high-uncertainty investment proposition. For investors interested in early-stage biotech, INDP offers a window into the speculative end of the healthcare sector—one where scientific promise and meaningful financial risk coexist.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Industry Biotechnology